Non-‘classical’ MEKs: A review of MEK3-7 inhibitors

Ada J. Kwong, Karl A. Scheidt*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

The MAPK pathways are an enduring area of interest due to their essential roles in cell processes. Increased expression and activity can lead to a multitude of diseases, sparking research efforts in developing inhibitors against these kinases. Though great strides have been made in developing MEK1/2 inhibitors, there is a notable lack of chemical probes for MEK3-7, given their central role in stimuli response, cell growth, and development. This review summarizes the progress that has been made on developing small molecule probes for MEK3-7, the specific disease states in which they have been studied, and their potential to become novel therapeutics.

Original languageEnglish (US)
Article number127203
JournalBioorganic and Medicinal Chemistry Letters
Volume30
Issue number13
DOIs
StatePublished - Jul 1 2020

Keywords

  • Drug discovery
  • Kinases
  • Mitogen-activated protein kinases
  • Small molecule inhibitors
  • Structure-activity relationships

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmaceutical Science
  • Drug Discovery
  • Clinical Biochemistry
  • Organic Chemistry

Fingerprint Dive into the research topics of 'Non-‘classical’ MEKs: A review of MEK3-7 inhibitors'. Together they form a unique fingerprint.

Cite this